Fact based stock research
Basilea (SWX:BSLN)


Basilea stock research in summary

basileapharma.com


Basilea shares have a SELL rating. While they show above average growth, they are bad value, and are riskily financed. We recommend selling Basilea shares.


Latest Obermatt Ranks


Country Switzerland
Industry Biotechnology
Index SPI
Size class X-Small

June 8, 2018. Top 10 stocks updated on Top 10 schedule or at least quarterly. ()




Research History: Basilea

STOCK RESEARCH SUMMARY 2015 2016 2017 2018
STOCK VALUE RANKS
27
30
19
27
STOCK GROWTH RANKS
32
74
86
92
STOCK SAFETY RANKS
17
13
26
8
COMBINED STOCK RANKS
13
26
23
33

Last update of Combined Rank: 8-Jun-2018. Stock research history is based on the Obermatt Method. The higher the rank, the better is Basilea in the corresponding investment strategy.


Value Metrics in Detail

Last update of Value Rank: 8-Jun-2018. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Basilea; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2015 2016 2017 2018
REVENUE GROWTH
70
72
89
90
PROFIT GROWTH
18
18
18
87
STOCK RETURNS
40
30
43
44
CONSOLIDATED RANK: GROWTH
32
74
86
92

Financial reporting date of Growth Rank: 31-Dec-2017. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Basilea.


Safety Metrics in Detail

SAFETY METRICS 2015 2016 2017 2018
LEVERAGE
80
63
50
66
REFINANCING
10
16
11
6
LIQUIDITY
15
10
10
13
CONSOLIDATED RANK: SAFETY
17
13
26
8

Financial reporting date of Safety Rank: 31-Dec-2017. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Basilea and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Basilea from June 8, 2018.